

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Akesobio

Akeso, Inc.

康方生物科技（開曼）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9926)

VOLUNTARY ANNOUNCEMENT

VESTING OF RESTRICTED SHARE UNITS UNDER THE PRE-IPO RSU SCHEME

This announcement is made by Akeso, Inc. (the “**Company**”) on a voluntary basis.

On December 1, 2022, an aggregate of 2,481,200 restricted share units (“**RSU(s)**”) granted under the restricted share unit scheme approved and adopted by the Company on August 29, 2019 (the “**Pre-IPO RSU Scheme**”) were vested to the relevant grantees under the Pre-IPO RSU Scheme (the “**RSU Vest**”). The shares of the Company (the “**Share(s)**”) underlying the awards granted under the Pre-IPO RSU Scheme are held by Aquae Hyperion Limited for the purpose of the trust established by the Company in respect of the Pre-IPO RSU Scheme (the “**ESOP Trust**”). Dr. XIA Yu, an executive director, chairwoman, president, and chief executive officer of the Company (“**Dr. Xia**”) acts as the settlor and enforcer of the ESOP Trust and is therefore deemed to be interested in the Shares held by Aquae Hyperion Limited under the Securities and Futures Ordinance (Cap. 571 of the laws of Hong Kong). As a result of the RSU Vest, the number of Shares held by Aquae Hyperion Limited was reduced to 25,979,879 Shares.

As of the date of this announcement, Dr. Xia is interested in an aggregate of 243,592,503 Shares (representing approximately 28.96% of the issued share capital of the Company), among which (a) 80,771,042 Shares are held through her wholly-owned holding company and her family trust, (b) 25,979,879 Shares are held by the ESOP Trust and are deemed to

be interested in by virtue of being the settlor and enforcer of the ESOP Trust, and (c) voting rights in 136,841,582 Shares which Dr. Xia is able to exercise as entrusted by Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell, Dr. ZHANG Peng and their controlled corporations.

By Order of the Board
Akeso, Inc.
Dr. XIA Yu
Chairwoman and executive director

Hong Kong, December 2, 2022

As at the date of this announcement, the Board of the Company comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Mr. XIA Yu (Ph.D.) as executive directors, Dr. ZHOU Yi and Mr. XIE Ronggang as non-executive directors, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.